293 related articles for article (PubMed ID: 33429247)
41. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR
Fu J; Yu J; Zhang X; Chang Y; Fan H; Dong M; Li M; Liu Y; Hu J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205605. PubMed ID: 37106478
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
Song Z; Jin Y; Ge Y; Wang C; Zhang J; Tang Z; Peng J; Liu K; Li Y; Ma X
Bioorg Med Chem; 2016 Nov; 24(21):5505-5512. PubMed ID: 27634676
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
Yang H; Yan R; Jiang Y; Yang Z; Zhang X; Zhou M; Wu X; Zhang T; Zhang J
Eur J Med Chem; 2020 Feb; 187():111966. PubMed ID: 31869655
[TBL] [Abstract][Full Text] [Related]
46. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Wakte PS
Bioorg Chem; 2021 Oct; 115():105226. PubMed ID: 34364055
[TBL] [Abstract][Full Text] [Related]
47. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
49. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Xiao Z; Chu C; Zhou L; Zhou Z; Zhang Q; Yang F; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Med Chem; 2020 Oct; 28(19):115669. PubMed ID: 32912435
[TBL] [Abstract][Full Text] [Related]
50. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.
Zhang H; Wu W; Feng C; Liu Z; Bai E; Wang X; Lei M; Cheng H; Feng H; Shi J; Wang J; Zhang Z; Jin T; Chen S; Hu S; Zhu Y
Eur J Med Chem; 2017 Jul; 135():12-23. PubMed ID: 28426996
[TBL] [Abstract][Full Text] [Related]
52. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
[TBL] [Abstract][Full Text] [Related]
53. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
54. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
55. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
56. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.
Zhang M; Yang Y; Wang Y; Wang J; Wu H; Zhu Y
Chem Pharm Bull (Tokyo); 2023 Feb; 71(2):140-147. PubMed ID: 36517026
[TBL] [Abstract][Full Text] [Related]
59. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR
Yu L; Huang M; Xu T; Tong L; Yan XE; Zhang Z; Xu Y; Yun C; Xie H; Ding K; Lu X
Eur J Med Chem; 2017 Jan; 126():1107-1117. PubMed ID: 28033579
[TBL] [Abstract][Full Text] [Related]
60. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
